AXL and esophageal squamous cell carcinoma: In our study, we investigated the prognostic relevance of AXL and HER2 expression in operable ESCC patients (116 cases) and the efficacy of the AXL inhibitor, foretinib [29], in wild type and HER2-resistant ESCC cells.